GlassScriptPhysician profile
David Nouri Rahimian
NPI 1386026060
$15,353.00
in general payments reported to CMS, 2019-2025
61 companies · $3,666 in 2025
The $3,666 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,900 · 2022: $2,165 · 2023: $3,066 · 2024: $4,556 · 2025: $3,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,288.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,687.10 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $1,120.85 | 2021-2025 | Ultomiris, Soliris |
| Pfizer INC. | $1,034.64 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $1,014.33 | 2021-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $977.21 | 2021-2025 | Xcopri |
| Lundbeck LLC | $764.96 | 2021-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $537.87 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Tg Therapeutics, INC. | $481.62 | 2024-2025 | |
| Amgen INC. | $475.02 | 2021-2025 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $438.42 | 2021-2025 | Hyqvia, Gammagard Liquid |
| Eisai INC. | $401.73 | 2022-2025 | |
| Biogen, INC. | $390.72 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Astrazeneca Pharmaceuticals LP | $382.65 | 2021-2025 | Wainua, Andexxa |
| Novartis Pharmaceuticals Corporation | $307.74 | 2021-2025 | |
| Chiesi USA, INC. | $260.40 | 2021-2024 | Cleviprex, Kengreal |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $220.63 | 2021-2025 | Bridion, Verquvo |
| Cumberland Pharmaceuticals, INC. | $219.13 | 2021-2025 | Caldolor |
| Horizon Therapeutics Plc | $217.93 | 2021-2023 | Uplizna |
| Impel Pharmaceuticals INC. | $213.73 | 2023 | Trudhesa |
| Emd Serono, INC. | $207.84 | 2022-2023 | Mavenclad |
| Grifols USA, LLC | $207.13 | 2022-2025 | Gamunex-C |
| Lilly USA, LLC | $192.89 | 2021-2025 | Kisunla, Amyvid, Reyvow |
| Amneal Pharmaceuticals LLC | $182.31 | 2025 | Crexont |
| Alnylam Pharmaceuticals INC. | $159.04 | 2021-2025 | Amvuttra |
| Genentech USA, INC. | $151.20 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Penumbra, INC. | $139.62 | 2022 | |
| Mallinckrodt Hospital Products INC. | $131.34 | 2022-2023 | Acthar |
| Amylyx Pharmaceuticals, INC. | $125.01 | 2024 | Relyvrio |
| Depuy Synthes Sales INC. | $125.00 | 2024 | Teligen |
| Kyowa Kirin, INC. | $120.37 | 2023-2025 | Nourianz |
| Scilex Pharmaceuticals INC. | $113.49 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $101.49 | 2021-2025 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $95.67 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $92.91 | 2021-2022 | |
| Corium, LLC | $92.89 | 2023 | Adlarity |
| Otsuka America Pharmaceutical, INC. | $91.18 | 2024-2025 | Rexulti |
| Merz Pharmaceuticals, LLC | $71.64 | 2023-2025 | Xeomin, Inbrija |
| Csl Behring | $68.50 | 2024-2025 | Hizentra |
| Axsome Therapeutics, INC. | $57.05 | 2025 | Symbravo |
| Mdd US Operations, LLC | $52.10 | 2024-2025 | Gocovri |
| Catalyst Pharmaceuticals, INC. | $49.56 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $48.23 | 2022 | |
| Acorda Therapeutics, INC | $44.24 | 2024 | Inbrija, Ampyra |
| Ucb, INC. | $44.06 | 2025 | Rystiggo, Fintepla |
| Tanabe Pharma America, INC. | $41.93 | 2022-2023 | |
| Banner Life Sciences, LLC | $38.53 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.13 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $32.62 | 2024 | Dysport |
| Vanda Pharmaceuticals INC. | $31.76 | 2024-2025 | Ponvory |
| Octapharma USA, INC. | $30.20 | 2022-2023 | Panzyga |
| Boston Scientific Corporation | $27.62 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Eagle Pharmaceuticals, INC. | $26.79 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $26.58 | 2025 | |
| Xeris Pharmaceuticals, INC. | $24.57 | 2023 | Keveyis |
| Supernus Pharmaceuticals, INC. | $22.94 | 2021 | |
| Genzyme Corporation | $21.93 | 2021 | |
| Azurity Pharmaceuticals, INC. | $19.62 | 2024 | Zonisade |
| Neurelis, INC. | $17.05 | 2023 | Valtoco |
| Celgene Corporation | $17.05 | 2022 | |
| Mylan Specialty L.P. | $16.19 | 2022 | |
| Ge Healthcare | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rahimian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.